CONMED Corporation — FY2014 Form 10-K Summary
Business context and reporting period
CONMED is a medical technology company providing surgical devices and equipment for minimally invasive procedures and monitoring, with product lines in orthopedic surgery, general surgery, and surgical visualization. The filing covers the fiscal year ended December 31, 2014; fourth-quarter data are unaudited.
- Approximately 3,500 employees; products sold in more than 100 foreign countries.
- 2014 sales mix: orthopedic surgery 54%, general surgery 38%, and surgical visualization 8%.
- Approximately 51% of consolidated sales were to customers outside the United States; approximately 36% were denominated in local currencies.
Financial performance and key metrics
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Net sales | $740.1 million | $762.7 million | Down 3.0% |
| Gross profit | $404.1 million | $412.4 million | Down 2.0% |
| Gross margin | 54.6% | 54.1% | Up 0.5 percentage points |
| Operating income | $52.8 million | $56.5 million | Down 6.6% |
| Operating margin | 7.1% | 7.4% | Down 0.3 percentage points |
| Net income | $32.2 million | $35.9 million | Down 10.4% |
| Diluted EPS | $1.16 | $1.28 | Down 9.4% |
| Cash flow from operations | $65.2 million | $80.9 million | Down 19.5% |
Capital equipment sales decreased 4.8% to $146.3 million, while single-use product sales decreased 2.5% to $593.8 million. Approximately 80% of revenue was derived from disposable products.
Fourth-quarter 2014 net sales were $195.0 million versus $203.4 million in the prior-year quarter. Gross profit was $104.0 million versus $111.4 million, while net income was $11.3 million versus $10.2 million. The filing does not provide a separately reported fourth-quarter operating margin.
Liquidity, debt, and capital allocation
- Cash and cash equivalents were $66.3 million at December 31, 2014, including approximately $63.9 million held by foreign subsidiaries outside the United States.
- Total debt was $241.4 million, including $235.0 million outstanding under a $350.0 million revolving credit facility and $6.4 million of mortgage debt. Available revolver capacity was $109.6 million, with approximately $5.4 million reserved for letters of credit.
- The revolving facility bears interest at LIBOR plus 1.625%; the rate was 1.785% at year-end. A 1-percentage-point increase in borrowing rates was estimated to reduce 2015 pre-tax income by approximately $2.4 million.
- Management stated that cash on hand, operating cash flow, and available borrowing capacity should be sufficient for expected operating needs, debt service, capital expenditures, and share repurchases.
- 2014 capital expenditures were $15.4 million. The company expects 2015 capital expenditures of approximately $15 million to $20 million.
- Dividends paid were $22.0 million, or $0.80 per share for the year. The company repurchased $16.9 million of common stock during 2014, with $37.4 million remaining under its authorized repurchase program.
- Remaining contingent consideration under the MTF sports-medicine allograft agreement was $33.4 million at year-end, including a $16.7 million payment made January 5, 2015.
Material changes versus the prior comparable period
- Sales declined across all product lines. Orthopedic surgery sales fell 1.8%, general surgery sales fell 2.5%, and surgical visualization sales fell 12.0%.
- Surgical visualization weakness was attributed partly to customers delaying purchases ahead of the IM8000 2DHD camera system, which had a limited U.S. release in the fourth quarter.
- Gross margin improved due primarily to restructuring-related manufacturing efficiencies, while operating and net margins declined because of lower sales and higher unusual expenses.
- Selling and administrative expense decreased to $293.9 million from $310.7 million, but research and development expense increased to $27.8 million from $25.8 million.
- Foreign exchange reduced 2014 sales by approximately $4.8 million and pre-tax income by approximately $2.4 million compared with 2013.
- Debt increased from $215.6 million at December 31, 2013 to $241.4 million at December 31, 2014.
- Operating cash flow decreased by $15.8 million, reflecting lower earnings and increased working capital requirements, including a $20.9 million increase in inventories.
Guidance, outlook, commentary, risks, and unusual items
- Management emphasized renewed research and development activity, including the IM8000 launch and forthcoming general-surgery products, expansion of orthopedic independent sales-agent groups, and selective acquisitions.
- The company expects to continue operational and administrative restructuring. It estimates 2015 restructuring costs of approximately $9 million to $11 million, net of tax.
- The Centennial, Colorado manufacturing consolidation is expected to be completed over the following 12 months. Management expects eventual annual cost-of-sales savings of approximately $3.5 million to $4.5 million, but stated that savings may not be evident for 12 months.
- 2014 other expense included $12.5 million of management restructuring costs, $4.0 million of shareholder-activism costs, $3.4 million of administrative consolidation costs, and $3.4 million of legal and other costs.
- The company acquired EndoDynamix in July 2014 for $1.3 million in cash and accrued $13.9 million of contingent consideration; $10.1 million remained outstanding at year-end.
- The FDA issued a January 2014 warning letter concerning the Centennial facility. A subsequent fourth-quarter 2014 inspection resulted in eight Form 483 observations, including three characterized as repeat observations. The company responded in December 2014, but had not received further FDA feedback as of the filing date.
- Key risks include foreign currency exposure, hospital capital-spending cycles, competitive pricing pressure, healthcare cost controls and reimbursement changes, regulatory compliance and potential product recalls, patent litigation, raw-material or supplier disruptions, acquisition integration, leverage and restrictive debt covenants, availability of allograft tissue, and management-transition execution.
- The company reported no material unresolved legal proceedings and stated that its disclosure controls and internal control over financial reporting were effective as of December 31, 2014.
Important facts for investors to verify
- Whether the IM8000 and planned general-surgery launches reverse the decline in surgical visualization and support sales growth.
- Progress, cost, timing, and FDA outcome of the Centennial facility remediation and consolidation.
- Execution of the estimated $9 million to $11 million of 2015 restructuring costs and realization of projected savings.
- Liquidity after the MTF contingent payments, debt maturities, dividends, repurchases, and acquisition-related obligations.
- Impact of foreign exchange movements on 2015 revenue and earnings, including the scope and duration of hedging coverage.
- Whether the company can maintain compliance with credit-agreement covenants while funding acquisitions, capital expenditures, dividends, and repurchases.
- Future developments in patent disputes, product liability, regulatory matters, and the availability of sports-medicine allograft tissue.